SMC provides advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the status of all newly licensed medicines. The SMC has completed its assessment of ustekinumab (also called Stelara) for people who have found that conventional therapy or a type of treatment called TNF-alpha inhibitors (infliximab or adalimumab) either don’t work for them, have stopped working or can’t be tolerated.
This important decision comes after Crohn’s & Colitis UK submitted evidence directly to the SMC in April. It is important for SMC members to fully understand how a new medicine impacts the quality of life of patients and carers. This enables them to make a fully informed decision on whether or not to recommend a new medicine.
Patient group submissions to SMC, like this one on ustekinumab, provide unique knowledge about what it's like to live with a condition and can make a huge difference to the final decisions.
We explained in our evidence that having control of the symptoms of Crohn’s Disease can have a life changing effect; enabling people to resume work and everyday activities as well as providing a new treatment option for some people for whom other treatments have not worked. One of our two Patient Experts gave compelling evidence to the National Institute for Health and Care (NICE) Appraisal committee in England backed up our evidence to the SMC:
Ustekinumab (Stelara) is already in use for psoriasis and psoriatic arthritis. It works in a different way from other biological drugs, currently available for Crohn’s Disease, by targeting two specific naturally occurring proteins which play a key role in inflammatory and immune responses. The first dose of ustekinumab would be given intravenously and further doses as a subcutaneous injection (under the skin), which can be self-administered, every 8 or 12 weeks.
Read more
- Final NICE guidance for England and Wales - NICE guidance is subject to a local review process in Northern Ireland, which begins once NICE has issued their final draft guidance.
- SMC advice
- Our submissions
The choice of treatment between ustekinumab or another biological therapy should be made on an individual basis after discussion between the patient and their clinician about the advantages and disadvantages of the treatments available.
Find out more information about: